Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Thrombocytopenia 4Lymphoma, Non-Hodgkin 4Multiple Myeloma 3Hodgkin Disease 2Solid Tumor 1Sarcoma, Ewing 1Ovarian Neoplasms 1Neoplasms 1Melanoma 1Lymphoma, Mantle-Cell 1Lymphoma 1Leukemia, Monocytic, Acute 1Leukemia, Lymphoid 1Hematologic Neoplasms 1Glioblastoma 1Chemotherapy-induced Thrombocytopenia 1

Interventions

Cytarabine 39Busulfan 15Idarubicin 14Cyclophosphamide 13Mitoxantrone 12Filgrastim 12Etoposide 12fludarabine phosphate 11Peripheral Blood Stem Cell Transplantation 11Daunorubicin 9Methotrexate 8Cyclosporine 8Tacrolimus 7Whole-Body Irradiation 5Mycophenolic Acid 5Clofarabine 5Cladribine 5Biopsy 5Azacitidine 5Arsenic Trioxide 5Antilymphocyte Serum 5Radiotherapy 4Gemtuzumab 4Flow Cytometry 4Decitabine 4Cyclosporins 4venetoclax 3pegylated granulocyte colony-stimulating factor 3Topotecan 3Injections 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Leukemia, Monocytic, Acute × romiplostim × Clear all
NCT02046291 2021-06-08

Safety of Romiplostim (Nplate®) Following UCBT

Masonic Cancer Center, University of Minnesota

Phase 1 Completed
21 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Leukemia, Lymphoid, Leukemia, Monocytic, Acute, Lymphoma, Non-Hodgkin, Multiple Myeloma, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡